Oculis S.A. is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.

Products, services, technology

OCS-01 being developed in DME and Post-ocular surgery inflammation;
OCS-02 being developed for Uveitis and Dry Eye;
Pre-clinical candidates for retinal disorders and for ocular inflammation

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    1-9
Key business